The combination of lanreotide 90 mg plus dexamethasone in the treatment of hormonerefractory prostate cancer (HRPCA)

dc.creator	Mitsogiannis, I.	en
dc.creator	Oeconomou, A.	en
dc.creator	Gravas, S.	en
dc.creator	Mitrakas, L.	en
dc.creator	Tzortzis, V.	en
dc.creator	Moutzouris, G.	en
dc.creator	Melekos, M.	en
dc.date.accessioned	2015-11-23T10:39:48Z
dc.date.available	2015-11-23T10:39:48Z
dc.date.issued	2007
dc.identifier	10.1016/s1569-9056(07)60312-1
dc.identifier.issn	1569-9056
dc.identifier.uri	http://hdl.handle.net/11615/31092
dc.source	European Urology Supplements	en
dc.source.uri	<Go to ISI>://WOS:000244422600314
dc.subject	Urology & Nephrology	en
dc.title	The combination of lanreotide 90 mg plus dexamethasone in the treatment of hormonerefractory prostate cancer (HRPCA)	en
dc.type	journalArticle	en

Files in questo item

Files	Dimensione	Formato	Mostra
Nessun files in questo item.